HYPERLIPOPROTEINEMIA IN ADULTS WITH RENAL-DISEASE

被引：4

作者：

ANDERSON, CF ^{[1
]}

机构：

[1] MAYO CLIN & MAYO FDN, DIV NEPHROL & INTERNAL MED, ROCHESTER, MN 55905 USA

来源：

MAYO CLINIC PROCEEDINGS | 1993年 / 68卷 / 04期

关键词：

D O I：

10.1016/S0025-6196(12)60131-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hyperlipoproteinemia is common in patients with renal disease, but increased lipids are only one of several risk factors frequently identified for coronary artery disease. Before treatment options are instituted, renal disease status, current medications, and possible interactions between drugs must be considered. Hypertriglyceridemia is common in patients with renal failure; therapeutic options are influenced by the levels of serum triglycerides and high-density lipoprotein cholesterol. If nonsteroidal drugs improve renal function and decrease proteinuria in patients with renal disease, hyperlipidemia frequently abates. Interactions between drugs are important considerations when lipid-lowering drug treatment is prescribed in recipients of renal transplants.

引用

页码：358 / 362

页数：5

共 26 条

[1]

[Anonymous], 1992, Med Lett Drugs Ther, V34, P57

[2] LIPID ABNORMALITIES IN RENAL-DISEASE [J].

APPEL, G ;

SCHAEFER, E ;

MADIAS, NE ;

MADAIO, MP ;

HARRINGTON, JT ;

LEVEY, AS ;

NARAYAN, G ;

MEYER, K .

KIDNEY INTERNATIONAL, 1991, 39 (01) :169-183

[3] THE HYPERLIPIDEMIA OF THE NEPHROTIC SYNDROME - RELATION TO PLASMA-ALBUMIN CONCENTRATION, ONCOTIC PRESSURE, AND VISCOSITY [J].

APPEL, GB ;

BLUM, CB ;

CHIEN, S ;

KUNIS, CL ;

APPEL, AS .

NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (24) :1544-1548

[4] LIPID AND APOLIPOPROTEIN PROFILES OF UREMIC DYSLIPOPROTEINEMIA - RELATION TO RENAL-FUNCTION AND DIALYSIS [J].

ATTMAN, PO ;

ALAUPOVIC, P .

NEPHRON, 1991, 57 (04) :401-410

[5] EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS .1. EFFICACY IN MODIFYING PLASMA-LIPOPROTEINS AND ADVERSE EVENT PROFILE IN 8245 PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA [J].

BRADFORD, RH ;

SHEAR, CL ;

CHREMOS, AN ;

DUJOVNE, C ;

DOWNTON, M ;

FRANKLIN, FA ;

GOULD, AL ;

HESNEY, M ;

HIGGINS, J ;

HURLEY, DP ;

LANGENDORFER, A ;

NASH, DT ;

POOL, JL ;

SCHNAPER, H .

ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (01) :43-49

[6]

CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36

[7] THE EFFECT OF RENAL-FUNCTION ON THE PHARMACOKINETICS OF GEMFIBROZIL [J].

EVANS, JR ;

FORLAND, SC ;

CUTLER, RE .

JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 27 (12) :994-1000

[8]

FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499

[9]

FRISHMAN WH, 1992, MED MANAGEMENT LIPID, P217

[10]

FROHLICH JJ, 1991, PRIMARY HYPERLIPOPRO, P143

← 1 2 3 →